Q4 2017 Earnings Forecast for Galmed Pharmaceuticals Ltd. Issued By Seaport Global Securities (GLMD)
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) – Equities research analysts at Seaport Global Securities boosted their Q4 2017 EPS estimates for shares of Galmed Pharmaceuticals in a research report issued to clients and investors on Monday. Seaport Global Securities analyst V. Bernardino now expects that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, up from their prior estimate of ($0.32). Seaport Global Securities has a “Buy” rating and a $19.00 price target on the stock. Seaport Global Securities also issued estimates for Galmed Pharmaceuticals’ FY2018 earnings at ($1.03) EPS, FY2019 earnings at $0.49 EPS, FY2020 earnings at ($0.23) EPS and FY2021 earnings at ($0.58) EPS.
Several other equities analysts have also recently weighed in on GLMD. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Maxim Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Galmed Pharmaceuticals in a research note on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $14.88.
A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. KCG Holdings Inc. acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals as of its most recent SEC filing. 8.25% of the stock is owned by institutional investors and hedge funds.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.